Repligen, MIT Sue ImClone Over Erbitux Patent
A drug maker and a university are suing Manhattan-based biotech company ImClone over patent rights to the drug at the center of the scandal that led to the trials of ImClone...To view the full article, register now.
Already a subscriber? Click here to view full article